OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Hyperimmune immunoglobulin for people with COVID-19
Catherine Kimber, Sarah J Valk, Khai Li Chai, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 16
Catherine Kimber, Sarah J Valk, Khai Li Chai, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 16
Showing 16 citing articles:
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Eva Stadler, Khai Li Chai, Timothy E. Schlub, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e883-e892
Open Access | Times Cited: 22
Eva Stadler, Khai Li Chai, Timothy E. Schlub, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e883-e892
Open Access | Times Cited: 22
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 5
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 5
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
Yasmin Maor, Eilat Shinar, Marina Izak, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 964-971
Open Access | Times Cited: 10
Yasmin Maor, Eilat Shinar, Marina Izak, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 964-971
Open Access | Times Cited: 10
Cochrane's COVID‐19 Living Systematic Reviews: A Mixed‐Methods Study of Their Conduct, Reporting and Currency
Kevindu De Silva, Tari Turner, Steve McDonald
Cochrane Evidence Synthesis and Methods (2025) Vol. 3, Iss. 3
Open Access
Kevindu De Silva, Tari Turner, Steve McDonald
Cochrane Evidence Synthesis and Methods (2025) Vol. 3, Iss. 3
Open Access
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19
Tayler A. Van Denakker, Arwa Z. Al‐Riyami, Rita Feghali, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 7, pp. 501-514
Closed Access | Times Cited: 8
Tayler A. Van Denakker, Arwa Z. Al‐Riyami, Rita Feghali, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 7, pp. 501-514
Closed Access | Times Cited: 8
Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 4
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 4
Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 4
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 4
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
Elizabeth J. Martinez, William C. Chang, Wei‐Hung Chen, et al.
iScience (2024) Vol. 27, Iss. 10, pp. 110624-110624
Open Access | Times Cited: 1
Elizabeth J. Martinez, William C. Chang, Wei‐Hung Chen, et al.
iScience (2024) Vol. 27, Iss. 10, pp. 110624-110624
Open Access | Times Cited: 1
Neutralization of Different Variants of SARS-CoV-2 by a F(ab’)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain
Mariajosé Rodríguez, Mariana del Valle Cepeda, Carlos Bello, et al.
(2023)
Open Access | Times Cited: 3
Mariajosé Rodríguez, Mariana del Valle Cepeda, Carlos Bello, et al.
(2023)
Open Access | Times Cited: 3
Neutralization of Different Variants of SARS-CoV-2 by a F(ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain
Mariajosé Rodríguez, Mariana del Valle Cepeda, Carlos Bello, et al.
Antibodies (2023) Vol. 12, Iss. 4, pp. 80-80
Open Access | Times Cited: 3
Mariajosé Rodríguez, Mariana del Valle Cepeda, Carlos Bello, et al.
Antibodies (2023) Vol. 12, Iss. 4, pp. 80-80
Open Access | Times Cited: 3
Mechanical ventilation core outcome set uptake in Cochrane systematic reviews: A cross‐sectional study
Luis Garegnani, Diego Ivaldi, Mariana Burgos, et al.
Cochrane Evidence Synthesis and Methods (2024) Vol. 2, Iss. 1
Open Access
Luis Garegnani, Diego Ivaldi, Mariana Burgos, et al.
Cochrane Evidence Synthesis and Methods (2024) Vol. 2, Iss. 1
Open Access
Immunoglobulin replacement to prevent infections in people with haematological malignancies and haematopoietic stem cell transplantation
Khai Li Chai, Erica M. Wood, Lise J Estcourt, et al.
Cochrane library (2024) Vol. 2024, Iss. 3
Open Access
Khai Li Chai, Erica M. Wood, Lise J Estcourt, et al.
Cochrane library (2024) Vol. 2024, Iss. 3
Open Access
Monoclonal Antibodies and Hyperimmune Immunoglobulins in the Next Pandemic
Massimo Franchini, Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access
Massimo Franchini, Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access
What are the benefits and harms of hyperimmune immunoglobulin (hIVIG) from human plasma for treating adults with moderate/severe COVID-19?
Agustín Ciapponi, Amin Sharifan
Cochrane Clinical Answers (2023)
Closed Access
Agustín Ciapponi, Amin Sharifan
Cochrane Clinical Answers (2023)
Closed Access
For adults with moderate/severe COVID-19, what are the effects of hyperimmune immunoglobulin, specifically equine polyclonal antibodies (EpAbs)?
Agustín Ciapponi, Sera Tort
Cochrane Clinical Answers (2023)
Closed Access
Agustín Ciapponi, Sera Tort
Cochrane Clinical Answers (2023)
Closed Access
